Ariana Pelosci, associate editor for CancerNetwork®, has been with the team since June 2021. She specializes both in web and print, and runs the social media for CancerNetwork®.
She is a graduate of the University of Delaware, where she studied Media Communications and minored in journalism and marketing. At heart, she is a Jersey girl, and you can always find her down the shore during her free time.
Ariana loves to read, specifically historical or contemporary fiction. Follow Ariana on Twitter @APelosci or email her at firstname.lastname@example.org.
18FDG-PET May Identify Patients With HER2-Positive Early Breast Cancer Benefiting from Chemo-Free HER2 BlockadeJune 29th 2021
18FDG-PET was successful in identifying patients with HER2-positive early-stage breast cancer who were more likely to benefit from chemotherapy-free treatment with trastuzumab and pertuzumab.
Decision for Retifanlimab Approval Deferred for SCAC Treatment by ODACJune 25th 2021
The Oncologic Drugs Advisory Committee has decided to wait until more results from a clinical trial of retifanlimab are available to make a final decision about approval in squamous cell carcinoma of the anal canal.
177Lu-PSMA-617 Earns FDA Breakthrough Designation for Metastatic Castration-Resistant Prostate CancerJune 17th 2021
Radioligand therapy 177Lu-PSMA-617 receives breakthrough designation from the FDA based on better overall survival outcomes in patients with metastatic castration-resistant prostate cancer.